MBX (MBX Biosciences) DeferredTaxAndRevenue : $0.00 Mil (As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is MBX Biosciences DeferredTaxAndRevenue?

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

MBX Biosciences's current deferred tax and revenue for the quarter that ended in Mar. 2025 was $0.00 Mil.

MBX Biosciences DeferredTaxAndRevenue Historical Data

The historical data trend for MBX Biosciences's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MBX Biosciences DeferredTaxAndRevenue Chart

MBX Biosciences Annual Data

Trend

Dec22

Dec23

Dec24

DeferredTaxAndRevenue

MBX Biosciences Quarterly Data
	Dec22	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
DeferredTaxAndRevenue	Get a 7-Day Free Trial			-	-	-	-	-

MBX Biosciences DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of MBX Biosciences's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.

MBX Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MBX Biosciences Inc (NAS:MBX) » Definitions » DeferredTaxAndRevenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

11711 N. Meridian Street, Suite 300, Carmel, IN, USA, 46032

Website

https://www.mbxbio.com

MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.